An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer

Emily Berry*, Kellie S. Matthews, Diljeet K. Singh, Barbara M. Buttin, John Robert Lurain III, Ronald D. Alvarez, Julian Schink

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Objectives: To assess the feasibility, associated toxicities, and reasons for early cessation of an outpatient intraperitoneal (IP) chemotherapy regimen for treatment of advanced ovarian cancer following optimal cytoreductive surgery. Methods: Between January 2006 and December 2007, 42 patients with stages IIC-IV epithelial ovarian, tubal, or primary peritoneal cancer who had residual disease < 1 cm after cytoreductive surgery were treated with an outpatient IP chemotherapy protocol. Patients received intravenous (IV) docetaxel 75 mg/m2 and IP cisplatin 75-100 mg/m2 on day 1, followed by IP paclitaxel 60 mg/m2 on day 8, with the intent to treat patients every 21 days for 6 cycles of chemotherapy. Charts were abstracted for demographic, chemotherapy, and toxicity-related data. Results: The median age of the 42 patients was 59 years (range 33-70) and the majority of patients had epithelial ovarian cancer (80%), FIGO stage IIIC (83%), and papillary serous histology (74%). Of an intended 252 IP chemotherapy cycles, 172 (68%) were administered. Twenty-nine patients (69%) completed ≥ 4 cycles and 12 (29%) received all 6 IP cycles. Common grade 3/4 toxicities by patient included neutropenia (43%), infection (21.5%), and gastrointestinal effects (14%). There was one treatment-related death. Reasons for discontinuation were largely chemotherapy (43%) or port (37%) related. Conclusions: With supportive measures, such as scheduled hydration and granulocyte colony-stimulating factors, outpatient administration of IP chemotherapy was feasible. This regimen resulted in few hospitalizations or treatment delays and demonstrated less toxicity than previously reported IP chemotherapy regimens. Port-related complications were a leading cause of IP chemotherapy discontinuation.

Original languageEnglish (US)
Pages (from-to)63-67
Number of pages5
JournalGynecologic Oncology
Issue number1
StatePublished - Apr 1 2009


  • Antineoplastic combined chemotherapy
  • Cisplatin
  • Intraperitoneal chemotherapy
  • Outpatient
  • Ovarian adenocarcinoma
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this